{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:45:42Z","timestamp":1792601142329,"version":"4.5.0"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Romosozumab is a monoclonal antibody approved for osteoporosis which targets sclerostin, an endogenous inhibitor of Wnt\/\u03b2-catenin pathway. Given the essential roles of the Wnt\/\u03b2-catenin pathway in various tissues, we hypothesized romosozumab treatment may influence other conditions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This cohort study included patients prescribed romosozumab or parathyroid receptor (PTHR) agonists after 1 January 2019, using a Japanese electronic medical record database. The outcomes of interest included autoimmune disease, interstitial pneumonia, cardiovascular outcome, Alzheimer\u2019s disease, Parkinson\u2019s disease (PD), serious infections, and malignancies. A stabilized inverse probability-weighted Cox proportional hazard model was used to estimate the hazard ratios. Age- and gender-based subgroup analyses were conducted. Exploratory outcomes based on three-digit International Classification of Diseases 10th Revision-based were also examined.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 2,673 patients treated with romosozumab and 5,980 treated with PTHR agonists were identified, respectively. While most outcomes of interest showed no association with romosozumab, the risk of PD decreased with romosozumab (hazard ratio [95% confidence interval], 0.37 [0.14\u20130.94]) compared with PTHR agonist. Regarding the cardiovascular outcome, no notable association was identified overall; however, gender-based subgroup analysis suggested that male sex may be a potential risk factor with romosozumab treatment. Only 16 of 903 exploratory outcomes were potentially influenced by romosozumab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Romosozumab lowered the risk of PD development compared with PTHR agonist. The study also highlights the utility of routinely collected health data for drug repositioning. While further validation is warranted, the findings suggest that the Wnt-\u03b2-catenin pathway holds promise as a therapeutic target for PD.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1411285","type":"journal-article","created":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T08:54:07Z","timestamp":1721638447000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Wnt\/\u03b2-catenin pathway as a potential target for Parkinson\u2019s disease: a cohort study of romosozumab using routinely collected health data in Japan"],"prefix":"10.3389","volume":"15","author":[{"given":"Shoichiro","family":"Inokuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Shimamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/mdc3.12568","article-title":"Epidemiology of Parkinson\u2019s disease\u2014east versus west","volume":"5","author":"Abbas","year":"2018","journal-title":"Mov. Disord. Clin. Pract."},{"key":"B2","unstructured":"U.S. Food and drug administration website2019"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1210\/en.2007-0270","article-title":"Targeting the Wnt\/beta-catenin pathway to regulate bone formation in the adult skeleton","volume":"148","author":"Baron","year":"2007","journal-title":"Endocrinology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1096\/fj.201600502r","article-title":"Wnt\/\u03b2\u2010catenin pathway in tissue injury: roles in pathology and therapeutic opportunities for regeneration","volume":"30","author":"Bastakoty","year":"2016","journal-title":"FASEB"},{"key":"B5","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J. R. Stat. Soc."},{"key":"B6","doi-asserted-by":"publisher","first-page":"13644","DOI":"10.1038\/s41598-018-28968-9","article-title":"Inhibition of Wnt\/\u03b2-catenin signaling suppresses myofibroblast differentiation of lung resident mesenchymal stem cells and pulmonary fibrosis","volume":"8","author":"Cao","year":"2018","journal-title":"Sci. Rep."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/s0002-9440(10)64282-4","article-title":"Aberrant Wnt\/beta-catenin pathway activation in idiopathic pulmonary fibrosis","volume":"162","author":"Chilosi","year":"2003","journal-title":"Am. J. Pathol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B9","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.1089\/scd.2011.0678","article-title":"Glycogen synthase kinase-3 inhibition promotes proliferation and neuronal differentiation of human-induced pluripotent stem cell-derived neural progenitors","volume":"21","author":"Esfandiari","year":"2012","journal-title":"Stem Cells Dev."},{"key":"B10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11914-020-00652-w","article-title":"Romosozumab: a review of efficacy, safety, and cardiovascular risk","volume":"19","author":"Fixen","year":"2021","journal-title":"Curr. Osteoporos. Rep."},{"key":"B11","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1038\/nm.1982","article-title":"Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells","volume":"15","author":"Gattinoni","year":"2009","journal-title":"Nat. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"109","DOI":"10.4103\/2229-3485.83221","article-title":"Intention-to-treat concept: a review","volume":"2","author":"Gupta","year":"2011","journal-title":"Perspect. Clin. Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2188\/jea.JE20200288","article-title":"History and profile of diagnosis procedure combination (DPC): development of a real data collection system for acute inpatient care in Japan","volume":"31","author":"Hayashida","year":"2021","journal-title":"J. Epidemiol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"114239","DOI":"10.1016\/j.ejmech.2022.114239","article-title":"Drug repositioning: progress and challenges in drug discovery for various diseases","volume":"234","author":"Hua","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1111\/jphp.13273","article-title":"Drug repositioning: a brief overview","volume":"72","author":"Jourdan","year":"2020","journal-title":"J. Pharm. Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"k3532","DOI":"10.1136\/bmj.k3532","article-title":"The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE)","volume":"363","author":"Langan","year":"2018","journal-title":"BMJ"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1523\/jneurosci.5259-11.2012","article-title":"Plasticity of subventricular zone neuroprogenitors in MPTP (1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine) mouse model of Parkinson\u2019s disease involves cross talk between inflammatory and Wnt\/\u03b2-catenin signaling pathways: functional consequences for neuroprotection and repair","volume":"32","author":"L\u2019Episcopo","year":"2012","journal-title":"J. Neurosci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1523\/JNEUROSCI.3206-12.2013","article-title":"Aging-induced Nrf2-ARE pathway disruption in the subventricular zone drives neurogenic impairment in parkinsonian mice via PI3K-Wnt\/\u03b2-catenin dysregulation","volume":"33","author":"L\u2019Episcopo","year":"2013","journal-title":"J. Neurosci."},{"key":"B19","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1002\/stem.1708","article-title":"Wnt\/\u03b2-catenin signaling is required to rescue midbrain dopaminergic progenitors and promote neurorepair in ageing mouse model of Parkinson's disease","volume":"32","author":"L\u2019Episcopo","year":"2014","journal-title":"Stem Cells"},{"key":"B20","doi-asserted-by":"publisher","first-page":"19883","DOI":"10.1074\/jbc.m413274200","article-title":"Sclerostin binds to LRP5\/6 and antagonizes canonical wnt signaling","volume":"280","author":"Li","year":"2005","journal-title":"J. Biol. Chem."},{"key":"B21","doi-asserted-by":"publisher","first-page":"17455057221125577","DOI":"10.1177\/17455057221125577","article-title":"Romosozumab for the treatment of osteoporosis in women: efficacy, safety, and cardiovascular risk","volume":"18","author":"Lim","year":"2022","journal-title":"Womens Health Lond Engl."},{"key":"B22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41392-021-00762-6","article-title":"Wnt\/\u03b2-catenin signalling: function, biological mechanisms, and therapeutic opportunities","volume":"7","author":"Liu","year":"2022","journal-title":"Signal Transduct. Target Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"681","DOI":"10.3233\/jpd-150685","article-title":"The concept of prodromal Parkinson\u2019s disease","volume":"5","author":"Mahlknecht","year":"2015","journal-title":"J. Park. Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e13101","DOI":"10.1111\/acel.13101","article-title":"Parkinson's disease, aging and adult neurogenesis: wnt\/\u03b2-catenin signalling as the key to unlock the mystery of endogenous brain repair","volume":"19","author":"Marchetti","year":"2020","journal-title":"Aging Cell"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1096\/fj.05-4221fje","article-title":"Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation","volume":"19","author":"Poole","year":"2005","journal-title":"FASEB J."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med. Care"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1038\/ki.2015.194","article-title":"Increased circulating sclerostin levels in end-stage renal disease predict biopsy-verified vascular medial calcification and coronary artery calcification","volume":"88","author":"Qureshi","year":"2015","journal-title":"Kidney Int."},{"key":"B28","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3390\/diseases11030089","article-title":"WNT-\u03b2 catenin signaling as a potential therapeutic target for neurodegenerative diseases: current status and future perspective","volume":"11","author":"Ramakrishna","year":"2023","journal-title":"Diseases"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1097\/EDE.0b013e3181a663cc","article-title":"High-dimensional propensity score adjustment in studies of treatment effects using health care claims data","volume":"20","author":"Schneeweiss","year":"2009","journal-title":"Epidemiology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.11005\/jbm.2023.30.1.1","article-title":"Molecular and cellular crosstalk between bone and brain: accessing bidirectional neural and musculoskeletal signaling during aging and disease","volume":"30","author":"Schurman","year":"2023","journal-title":"J. Bone Metab."},{"key":"B32","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s42255-024-00989-x","article-title":"Osteocyte-derived sclerostin impairs cognitive function during ageing and Alzheimer\u2019s disease progression","volume":"6","author":"Shi","year":"2024","journal-title":"Nat. Metab."},{"key":"B33","doi-asserted-by":"publisher","first-page":"6500","DOI":"10.1007\/s12035-017-0860-4","article-title":"Glycogen synthase kinase-3\u03b2 regulates equilibrium between neurogenesis and gliogenesis in rat model of Parkinson\u2019s disease: a crosstalk with wnt and notch signaling","volume":"55","author":"Singh","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"a009399","DOI":"10.1101\/cshperspect.a009399","article-title":"\u03b1-Synuclein in Parkinson\u2019s disease","volume":"2","author":"Stefanis","year":"2012","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"dgae173","DOI":"10.1210\/clinem\/dgae173","article-title":"Cardiovascular safety of romosozumab vs. PTH analogs for osteoporosis treatment: a propensity score matched cohort study","volume":"14","author":"Stokar","year":"2024","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B36","doi-asserted-by":"publisher","first-page":"602330","DOI":"10.3389\/fimmu.2021.602330","article-title":"The roles of sclerostin in immune system and the applications of aptamers in immune-related research","volume":"12","author":"Sun","year":"2021","journal-title":"Front. Immunol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1164\/rccm.201205-0972OC","article-title":"\u03b2-catenin in the alveolar epithelium protects from lung fibrosis after intratracheal bleomycin","volume":"187","author":"Tanjore","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.4049\/jimmunol.1800633","article-title":"The role of WNT signaling in mature T cells: T cell factor is coming home","volume":"201","author":"van Loosdregt","year":"2018","journal-title":"J. Immunol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.3390\/jcm10081660","article-title":"Cardiovascular safety profile of romosozumab: a pharmacovigilance analysis of the US Food and drug administration adverse event reporting system (FAERS)","volume":"10","author":"Vestergaard Kvist","year":"2021","journal-title":"J. Clin. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s10916-008-9220-2","article-title":"Impact of the Japanese diagnosis procedure combination-based payment system in Japan","volume":"34","author":"Wang","year":"2010","journal-title":"J. Med. Syst."},{"key":"B41","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1002\/sim.2174","article-title":"Adjusted Kaplan-Meier estimator and log-rank test with inverse probability of treatment weighting for survival data","volume":"24","author":"Xie","year":"2005","journal-title":"Stat. Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1524-4733.2009.00671.x","article-title":"Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals","volume":"13","author":"Xu","year":"2010","journal-title":"Value Health"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1200\/jco.19.01186","article-title":"Medication-related osteonecrosis of the jaw: MASCC\/ISOO\/ASCO clinical practice guideline","volume":"37","author":"Yarom","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41392-021-00701-5","article-title":"Wnt\/\u03b2-catenin signaling in cancers and targeted therapies","volume":"6","author":"Yu","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"key":"B45","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3233\/jad-181249","article-title":"The potential influence of bone-derived modulators on the progression of Alzheimer\u2019s disease","volume":"69","author":"Yuan","year":"2019","journal-title":"J. Alzheimers Dis."},{"key":"B46","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41514-023-00114-4","article-title":"Elevated plasma sclerostin is associated with high brain amyloid-\u03b2 load in cognitively normal older adults","volume":"9","author":"Yuan","year":"2023","journal-title":"NPJ Aging"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1038\/onc.2016.304","article-title":"Wnt signaling in cancer","volume":"36","author":"Zhan","year":"2017","journal-title":"Oncogene"},{"key":"B48","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s13045-020-00990-3","article-title":"Targeting the Wnt\/\u03b2-catenin signaling pathway in cancer","volume":"13","author":"Zhang","year":"2020","journal-title":"J. Hematol. Oncol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1411285\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T08:54:19Z","timestamp":1721638459000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1411285\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,22]]},"references-count":48,"alternative-id":["10.3389\/fphar.2024.1411285"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1411285","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,22]]},"article-number":"1411285"}}